Inspira Technologies OXY has announced that its artificial intelligence (AI)-driven HYLA blood sensor achieved 96% accuracy for a key parameter in a clinical trial.
The Nasdaq-listed company specialises in life-support and diagnostic technologies.
Inspira Technologies said that the results are pivotal in its efforts to advance real-time blood monitoring technology, which aims to replace traditional methods requiring intermittent sampling.
The HYLA sensor leverages AI technology to continuously track various blood parameters, offering immediate data that could lead to faster medical interventions.
Unlike conventional blood monitoring techniques, which depend on periodic sampling, the HYLA sensor provides continuous insights into patient conditions.
As an independent product, HYLA is targeting the blood gas analyser market. When integrated with Inspira Technologies’ respiratory support systems, it is expected to enhance the company’s position in the mechanical ventilation market.
The sensor is being developed for use across diverse clinical environments, such as intensive care units and operating theatres, with potential applications in cardiopulmonary bypass and critical care.
HYLA’s clinical trial also tested new parameters, which include a new indicator for detecting oxygen deficiencies, where it showed 92.3% accuracy. The collected data will be used to refine the AI algorithms and improve system precision further, facilitating continuous monitoring that could avert oxygen deficiency during surgical procedures without requiring blood draws.
The trial involved six patients undergoing open-heart surgery, utilising the clip-on HYLA sensor at two points along the blood circuit tubing to monitor flow during bypass operations. The device’s accuracy was validated by comparing its readings with those from standard blood analyser tests.
Conducted at Sheba Hospital in Israel, the study included collaboration between the hospital’s medical team and authorised representatives from Inspira Technologies.
With a focus on assessing accuracy against current hospital lab methods, Inspira Technologies plans to expand the study to collect more patient data, enhancing the AI learning capabilities of its system and driving forward early detection diagnostics software.
Inspira Technologies expects these results will support a submission to the US Food and Drug Administration (FDA) for the first configuration of HYLA by late 2025. Upon receiving FDA approval, the company plans to deploy its INSPIRA ART core technology across US hospitals to facilitate additional data gathering and conduct post-market assessments.
